Krka d. d (KRK.WA) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Poland · ISIN SI0031102120

Price
258.60 PLN
Market cap
8.05 bn PLN
P/E (2025)
19.96
P/S (2025)
3.94
Dividend yield
3.51 %
Net margin
19.76 %
Return on equity (ROE)
17.10 %
Return on assets (ROA)
13.25 %

Krka d. d financials

Fiscal year20242025
Revenue1.91 bn EUR2.04 bn EUR
Gross profit1.09 bn EUR1.18 bn EUR
Operating income427.57 m EUR457.20 m EUR
EBIT419.56 m EUR457.20 m EUR
Net income356.99 m EUR403.43 m EUR
Diluted EPS – continuing operations11.60 EUR12.96 EUR

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Krka d. d

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives. In addition, the company offers animal health products, including antiparasitics, antimicrobials, and other products. Further, it provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.10.2026. Details in the risk notice.

Krka d. d stock (KRK.WA): P/E, revenue, dividend | finmetric